CIK 0001590560
- Large accelerated filer
uniQure N.V.
Sign in to watch- Ticker
- QURE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- Phone
- +1 339-970-7000
- Business address
- PAASHEUVELWEG 25A, AMSTERDAM, Netherlands, 1105 BP
- Former names
- uniQure B.V.
- 4 Planned sale Director sold 2,645 shares at $30.01 ($79,376)
- 4 Planned sale Chief Medical Officer sold 45,000 shares at an average $25.06 ($1,127,500)
- 4 Grant or award Chief Customer & Strat Officer acquired 19,800 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale CEO, Managing Director sold 14,581 shares at $9.06 ($132,104)
- 4 Open-market sale Chief Medical Officer sold 808 shares at $9.06 ($7,320)
- 4 Open-market sale Chief Legal Officer sold 3,412 shares at $9.06 ($30,913)
- 4 Open-market sale Chief Financial Officer sold 12,000 shares at $9.06 ($108,720)
- 4 Open-market sale CEO, Managing Director sold 34,437 shares at $9.95 ($342,648)
- 4 Open-market sale Chief Financial Officer sold 12,532 shares at $9.95 ($124,693)
- 4 Open-market sale Chief Legal Officer sold 8,578 shares at $9.95 ($85,351)
- 4 Open-market sale Chief Medical Officer sold 1,660 shares at $9.95 ($16,517)
- 4 Open-market sale CEO, Managing Director sold 12,378 shares at $23.86 ($295,339)
- 4 Open-market sale Chief Financial Officer sold 6,217 shares at $23.86 ($148,338)
- 4 Planned sale Director sold 25,613 shares at an average $24.62 ($630,483)
- 4 Planned sale Director sold 6,390 shares at $27.28 ($174,319)
- 4 Planned sale Director sold 31,434 shares at an average $27.26 ($856,881)
- 4 Planned sale Director sold 38,810 shares at an average $30.34 ($1,177,517)
- 4 Planned sale CEO, Managing Director sold 226,316 shares at an average $41.46 ($9,382,473)
- 4 Planned sale Chief Financial Officer sold 18,000 shares at an average $52.51 ($945,120)
Page 2 of 22 · 433 filings